EPA DHA Omega 3 Ingredients Market

EPA DHA Omega 3 Ingredients Market Size, Market Forecast and Outlook By FMI

In 2025, the EPA DHA omega-3 ingredients market was valued at USD 3.40 billion. Based on Future Market Insights' analysis, demand for EPA DHA omega-3 ingredients is estimated to grow to USD 3.62 billion in 2026 and USD 6.80 billion by 2036. FMI projects a CAGR of 6.5% during the forecast period.

Absolute dollar growth of USD 3.18 billion over the decade reflects sustained clinical evidence accumulation supporting EPA and DHA omega-3 supplementation for cardiovascular, cognitive, infant brain development, and anti-inflammatory applications, driving dietary supplement, functional food, pharmaceutical, and infant formula demand across both established and emerging markets. Louis Dreyfus Company's October 2025 completion of the BASF Food and Health Performance Ingredients business acquisition, including the omega-3 oils portfolio for human nutrition, transfers BASF's established omega-3 production and formulation capabilities into LDC's global food and commodity ingredients distribution network. [1]

Summary of EPA DHA Omega 3 Ingredients Market

• EPA DHA Omega 3 Ingredients Market Definition
  • The market covers EPA and DHA omega-3 fatty acid ingredients from marine oil, algae oil, and high-purity concentrate sources in oil, powder, and encapsulated forms for dietary supplement, functional food, pharmaceutical, infant formula, and pet food applications.
• Demand Drivers in the Market
  • Louis Dreyfus Company's October 2025 completion of the acquisition of BASF's Food and Health Performance Ingredients business, including its omega-3 oil portfolio for human nutrition, transferring BASF's established omega-3 production and formulation capabilities into LDC's global food and health ingredients distribution infrastructure. [1]
  • KD Pharma Group's December 2025 signing of a definitive agreement to acquire the distribution and supply business for food-grade oils from dsm-firmenich, following KD Pharma's earlier 2024 and 2025 consolidation of dsm-firmenich's marine lipids business including the MEG-3 brand, solidifying KD Pharma's position as the world's leading producer of omega-3 fatty acids for pharmaceutical and nutraceutical markets. [2]
  • Aker BioMarine's January 2026 expansion in the Indian market, headlined by the introduction of Revervia, a high-concentration algae-based DHA solution produced through natural fermentation rather than chemical concentration, along with establishment of strategic leadership partnerships ahead of Vitafoods India 2026 to develop the algae omega-3 category in the high-growth Indian dietary supplement market. [3]
• Key Segments Analyzed in the FMI Report
  • Product: DHA holds 53.6% of product share in 2026, reflecting the priority clinical evidence base for DHA supplementation in infant brain and retinal development, adult cognitive function, and pregnancy nutrition that drives the highest-value application segments including infant formula DHA fortification and prenatal supplement formulations.
  • Source: Algae Oil accounts for 28.4% of source share in 2026, the fastest-growing source segment as algae DHA's fish-free, vegan, and sustainable positioning expands its addressable market from vegetarian and vegan supplement consumers into mainstream infant formula and functional food applications where fish-free sourcing provides regulatory and consumer acceptance advantages.
  • Application: Dietary Supplements represent 37.2% of application value in 2026, anchored by consumer omega-3 supplementation for cardiovascular, cognitive, and anti-inflammatory health outcomes, with premium triglyceride-form and rTG-form concentrate products commanding the highest per-unit values in the sports nutrition, prenatal, and premium wellness supplement channels.
• Analyst Opinion at FMI
  • Nandini Roy Choudhury, Principal Consultant for Food & Beverage Industry at Future Market Insights, opines, "In the updated version of the EPA DHA Omega-3 Ingredients Market Report for 2026 to 2036, CXOs will find that the LDC acquisition of BASF's omega-3 portfolio and KD Pharma's sequential consolidation of dsm-firmenich's marine lipid business are compressing the number of independent production-scale omega-3 ingredient suppliers from five to effectively three within a 15-month window, creating a supplier concentration dynamic that procurement teams at major supplement contract manufacturers and infant formula producers must actively manage through dual-qualification strategies. My findings indicate that Corbion's January 2026 Chinese regulatory approval for algae DHA and Aker BioMarine's Revervia India launch represent the algae route's strategic counterplay to marine oil consolidation, providing procurement teams with a structurally independent supply alternative whose cost trajectory will reach parity with marine oil concentrates in high-value applications by approximately 2028."
• Strategic Implications / Executive Takeaways
  • Qualify algae DHA suppliers including Corbion and Aker BioMarine Revervia alongside marine oil concentrate suppliers in your omega-3 ingredient sourcing matrix to maintain supply security as LDC-BASF and KD Pharma-dsm-firmenich consolidation reduces the number of independent marine oil production-scale suppliers and concentrates pricing leverage in fewer hands.
  • Develop infant formula DHA fortification specifications that can accommodate both algae oil DHA and marine oil DHA sources, as regulatory approval for algae DHA in infant formula has expanded to Australia following Corbion's Chinese approval and Arla's FSANZ MFGM approval precedent, enabling procurement flexibility between fish-free algae DHA and marine oil DHA dependent on market-specific regulatory status.
  • Build position in the Indian dietary supplement omega-3 market ahead of Aker BioMarine's Revervia rollout at Vitafoods India 2026, where algae DHA's fish-free positioning aligns with India's large vegetarian consumer population and provides a structural market access advantage for algae omega-3 brands over marine oil products that face consumer acceptability barriers in vegetarian household segments.
• Methodology
  • Validated through primary interviews with EPA DHA omega-3 ingredient producers and dietary supplement contract manufacturers, supported by Louis Dreyfus Company and KD Pharma Group acquisition announcement documentation.
  • Grounded in Aker BioMarine India expansion press releases, Corbion Chinese regulatory approval documentation, Global Omega-3 Day 2026 industry reporting, and EFSA omega-3 health claim approval data.
  • Zero reliance on speculative third-party market research; all forecasts reflect verifiable acquisition completions, confirmed regulatory approvals, and product launch documentation from primary corporate and regulatory sources.

As the acquisition completion announcement noted, LDC 'successfully completed the sale of BASF's Food and Health Performance Ingredients Business,' with the transfer including omega-3 oils for human nutrition as a core component of the performance ingredients portfolio being integrated into LDC's food and health ingredients business. [1]

China leads growth at 8.8% CAGR through 2036, driven by expanding middle class dietary supplement consumption, regulatory approval for omega-3 health claims in functional food, and infant formula DHA fortification mandate enforcement. India grows at 8.1%, underpinned by rising omega-3 nutritional awareness, growing supplement retail, and expanding functional food penetration. Germany grows at 7.5%, France at 6.8%, the UK at 6.2%, the USA at 5.5%, and Brazil at 4.9%. DHA holds 53.6% of product share; Algae Oil accounts for 28.4% of source share; Dietary Supplements represent 37.2% of application value.

EPA DHA Omega 3 Ingredients Market Definition

The EPA DHA omega-3 ingredients market encompasses the global production, trade, and commercial application of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) as long-chain omega-3 polyunsaturated fatty acid ingredients sourced from marine oils including anchovy, sardine, tuna, salmon, cod liver, krill, and menhaden, from algae-based fermentation and cultivation producing DHA-rich algae oil, and from high-purity concentrates. The market covers EPA and DHA ingredients in oil, powder, and encapsulated forms for dietary supplement softgel and liquid fill, functional food fortification, pharmaceutical omega-3 prescription and OTC applications, infant formula and baby food DHA fortification, and pet food and animal feed omega-3 applications.

EPA DHA Omega 3 Ingredients Market Inclusions

The report includes comprehensive global and regional market sizing by value with a 10-year forecast from 2026 to 2036. Segmental analysis covers product, source, and application dimensions. Country-level CAGR analysis includes China, India, Germany, France, the UK, the USA, and Brazil. Louis Dreyfus Company BASF omega-3 acquisition impact, KD Pharma Group dsm-firmenich food-grade oil acquisition, Aker BioMarine India market expansion with Revervia algae DHA, Corbion Chinese regulatory approval for algae DHA, and competitive positioning among Koninklijke DSM, BASF (legacy), Nordic Naturals, Clover Corporation, Omega Protein, and GC Rieber are incorporated.

EPA DHA Omega 3 Ingredients Market Exclusions

The scope excludes short-chain omega-3 alpha-linolenic acid (ALA) from flaxseed oil, chia seed oil, and walnut oil that does not require conversion to EPA or DHA for commercial omega-3 ingredient classification. Plant-based ALA omega-3 oil products are excluded unless they specifically contain EPA or DHA fractions produced through algae fermentation or chemical concentration. Fish oil products containing less than 10% combined EPA and DHA by weight are outside the defined concentrate specification scope.

EPA DHA Omega 3 Ingredients Market Research Methodology

• Primary Research: Interviews were conducted with EPA DHA omega-3 ingredient producers, dietary supplement contract manufacturers specifying omega-3 oil quality parameters, infant formula DHA ingredient procurement specialists, functional food omega-3 fortification technologists, and regulatory affairs specialists tracking EFSA omega-3 health claim approvals and FDA GRAS status for algae DHA and marine oil EPA DHA products.
• Desk Research: Louis Dreyfus Company BASF acquisition completion announcements, KD Pharma Group dsm-firmenich food-grade oil acquisition press releases, Aker BioMarine India expansion announcements including Revervia algae DHA launch documentation, Corbion Chinese regulatory approval for algae DHA products, Global Omega-3 Day 2026 industry report on EPA DHA importance across life stages, and producer annual reports covering omega-3 ingredient segment revenue supported the quantitative base.
• Market-Sizing and Forecasting: A hybrid bottom-up and top-down model reconstructed demand from dietary supplement omega-3 product retail volume by region, infant formula DHA fortification requirements by market and birth rate projections, functional food omega-3 fortification market data, pharmaceutical omega-3 prescription and OTC product volume, and pet food omega-3 supplementation adoption rates, validated against producer shipment data and known capacity additions.
• Data Validation and Update Cycle: Outputs underwent cross-validation against clinical study publication volume for EPA and DHA health outcomes, consumer omega-3 supplement purchase intent surveys, infant formula DHA regulatory requirement changes by market, anomaly screening, and expert review by omega-3 nutrition scientists and marine lipid industry specialists prior to release.

Why is the Epa Dha Omega 3 Ingredients Market Growing?

The EPA DHA Omega 3 ingredients market is expanding steadily due to growing consumer awareness about the health benefits of omega-3 fatty acids. Increasing focus on cardiovascular health, cognitive function, and overall wellness has driven demand for EPA and DHA enriched products. Innovations in sourcing and extraction techniques have improved ingredient purity and sustainability.

The rising preference for plant-based and clean-label products has fueled interest in algae oil as a sustainable and vegetarian source of omega-3s. Additionally, the dietary supplements segment has experienced consistent growth as consumers seek convenient ways to meet their nutritional needs.

Public health campaigns and dietary guidelines emphasizing omega-3 intake have further propelled market demand. Looking ahead, the market is expected to benefit from expanded applications across food and beverage sectors alongside supplements. Segmental growth is anticipated to be driven by DHA as the dominant product, algae oil as a key sustainable source, and dietary supplements as the primary application area.

Segmental Analysis

The EPA DHA omega-3 ingredients market is segmented by product, source, and application and geographic regions. The product of the EPA DHA omega-3 ingredients market is divided into DHA and EPA. In terms of the source of the EPA DHA omega-3 ingredients, the market is classified into Algae oil, Anchovy/Sardine Oils, High concentrates, Medium Concentrates, Low concentrates, Tuna oil, Cod liver oil, Salmon oil, Krill oil, and Menhaden oil. Based on the application of the EPA DHA omega-3 ingredients, the market is segmented into Dietary Supplements, Functional Food, Pharmaceutical Food, Infant Food, Pet & Animal Feed, and Others. Regionally, the EPA DHA omega-3 ingredients industry is classified into North America, Latin America, Western Europe, Eastern Europe, Balkan & Baltic Countries, Russia & Belarus, Central Asia, East Asia, South Asia & Pacific, and the Middle East & Africa.

Insights into the Product Segment: DHA

The DHA segment is projected to hold 53.6% of the market revenue in 2026, establishing it as the leading product category. This growth has been driven by DHA’s critical role in brain and eye health, which consumers and healthcare professionals have widely recognized. DHA is often preferred in formulations targeting maternal health, infant nutrition, and cognitive support, leading to increased inclusion in supplements and fortified foods.

Advances in extraction and concentration technologies have enhanced DHA bioavailability and stability. Furthermore, ongoing research highlighting DHA’s benefits has strengthened consumer trust and demand.

The segment benefits from its established health claims and regulatory approvals, reinforcing its position as a market leader.

Insights into the Source Segment: Algae Oil

The algae oil source segment is expected to account for 28.4% of the market revenue in 2026, reflecting growing interest in sustainable and plant-based omega-3 sources. Algae oil offers an environmentally friendly alternative to traditional fish oil, addressing concerns about overfishing and ocean pollution. The segment has been favored by vegan and vegetarian consumers as well as those seeking clean-label products.

Technological advancements have improved algae cultivation and extraction efficiencies, reducing production costs and enhancing product quality. Additionally, algae oil has been incorporated into a wide range of product formats including capsules, beverages, and functional foods.

As sustainability becomes a key purchasing factor, algae oil is expected to gain further traction as a preferred omega-3 source.

Insights into the Application Segment: Dietary Supplements

The dietary supplements application segment is projected to represent 37.2% of the market revenue in 2026, maintaining its leading role. Growth in this segment has been propelled by increasing consumer inclination toward proactive health management and nutritional supplementation. Dietary supplements offer a convenient and effective way to deliver EPA and DHA, meeting the daily recommended intake for various population groups.

The segment’s expansion has been supported by diverse product formats such as soft gels, gummies, and liquids that cater to different consumer preferences. Moreover, the rise in e-commerce and direct-to-consumer sales channels has facilitated easier access to omega-3 supplements globally.

As awareness about the benefits of omega-3 fatty acids continues to grow, the dietary supplements segment is expected to sustain its market dominance.

What are the Drivers, Restraints, and Key Trends of the EPA DHA Omega 3 Ingredients Market?

Demand for EPA DHA omega-3 ingredients is accelerating as dietary supplement, functional food, and infant formula sectors expand globally. Sales of algae- and fish-derived concentrates are gaining traction amid formulation innovation, regional regulatory shifts, and premium-positioned heart, brain, and prenatal health products.

Formulation Advancements in Concentrates Drive Adoption in Functional Categories

Demand for high-purity EPA DHA omega-3 concentrates increased 19% in 2025, with formulators in Japan, Germany, and South Korea favoring microencapsulated powders for fortified beverages and dairy. Suppliers scaled up 70% EPA concentrates with oxidation levels below 5 meq/kg, targeting sports nutrition and brain health SKUs. USA brands launched gummies with triglyceride-form omega-3s showing 1.6× higher bioavailability than ethyl esters, prompting a 22% rise in repeat purchases. In India and Brazil, omega-3 fortified baby cereals and yogurts entered mid-tier retail channels, supported by oil-stabilization innovations that extended shelf life by 9 months under ambient conditions.

Sales of Algal Omega-3 Ingredients Accelerate Amid Sustainability and Allergen-Free Positioning

Sales of algal EPA DHA omega-3 rose 27% YoY in 2025 as plant-based nutrition trends converged with allergen-sensitive demand. Infant formula manufacturers in China and the EU switched from fish oil to algae-based DHA to meet clean-label and vegan certification requirements. Prenatal supplement brands adopted hexane-free algal oils, citing traceability and marine toxin avoidance. USA medical nutrition companies incorporated algae-derived omega-3s into parenteral emulsions and dysphagia-compatible formats, supported by GRAS and EFSA-compliant status. Production volumes in closed photobioreactors increased by 38%, lowering heavy metal risk and ensuring consistent EPA: DHA ratios for clinical and pharmaceutical applications.

Analysis of EPA DHA Omega 3 Ingredients Market By Key Countries

Country	CAGR
China	8.8%
India	8.1%
Germany	7.5%
France	6.8%
UK	6.2%
USA	5.5%
Brazil	4.9%

The EPA-DHA omega-3 ingredients market is projected to grow globally at a CAGR of 6.5% from 2026 to 2036. China is setting the pace with a CAGR of 8.8%, fueled by rising nutraceutical production and domestic dietary supplement consumption. India follows at 8.1%, driven by growing functional food demand and a maturing clinical nutrition sector. Among OECD nations, Germany is progressing at 7.5%, reflecting strong pharma-grade EPA-DHA applications and consumer health awareness. The UK is expanding at a moderate 6.2%, supported by preventive healthcare focus and premium product uptake.

The USA is lagging slightly at 5.5%, where market maturity and strict regulatory compliance temper acceleration. This performance mix highlights how BRICS countries, particularly China and India, are scaling supply and demand faster, while OECD economies maintain steady momentum through innovation, clinical backing, and established retail channels in omega-3-based wellness. The report provides insights across 40+ countries. The five below are highlighted for their strategic influence and growth trajectory.

Sales Outlook for EPA DHA Omega-3 Ingredients Market in China

China’s EPA DHA omega-3 ingredients market is expected to grow at a CAGR of 8.8% between 2026 and 2036, driven by rising demand from functional foods, maternal nutrition, and pediatric health supplements. From 2020 to 2024, growth was primarily seen in fish oil capsules and imported prenatal supplements. Moving forward, the market is transitioning toward microencapsulated omega-3 powders and algal-based sources to meet clean-label and vegetarian consumer trends. Domestic supplement brands are scaling up R&D and in-house formulation of EPA-DHA blends to reduce reliance on imports and target health-conscious urban consumers.

• Functional beverage manufacturers are incorporating encapsulated omega-3s.
• Algal omega-3 production is expanding in response to plant-based demand.
• Maternal and child health segments are key drivers of premium omega-3 usage.

Market Forecast for EPA DHA Omega-3 Ingredients Market in India

India’s EPA DHA omega-3 ingredients market is projected to grow at a CAGR of 8.1% from 2026 to 2036, led by increased awareness of heart health and cognitive development supplements. During 2020-2024, omega-3 consumption remained niche, focused mostly in urban nutraceutical markets. The next decade is expected to witness broader penetration via fortified foods and personalized nutrition packs. Indian startups are launching value-priced fish oil capsules targeting middle-income groups, while contract manufacturers are introducing vegan omega-3 options derived from marine microalgae for Ayurvedic and holistic medicine lines.

• Heart health awareness campaigns are boosting EPA-DHA supplement sales.
• Vegan-friendly omega-3 ingredients are gaining interest in wellness stores.
• Food fortification programs are integrating omega-3s into mass-market products.

Growth and Expansion Outlook for EPA DHA Omega-3 Ingredients Market in Germany

Germany’s EPA DHA omega-3 ingredients market is projected to expand at a CAGR of 7.5% from 2026 to 2036, supported by strong demand for brain health and cardiovascular supplements among the aging population. Between 2020 and 2024, growth was driven by prescription omega-3 formulations and OTC supplements. In the coming years, dietary supplement companies are expected to launch EPA-DHA combinations with co-nutrients like vitamin D and CoQ10, targeting bioavailability and compliance. Consumer interest in sustainable sourcing is also pushing manufacturers to invest in Friend of the Sea-certified fish oils and algae-based solutions.

• Aging demographics are driving interest in high-purity omega-3 blends.
• Co-formulations with heart-health nutrients are gaining retail shelf space.
• Sustainability certifications are influencing ingredient procurement decisions.

In-depth Analysis of EPA DHA Omega-3 Ingredients Market in the United Kingdom

The EPA DHA omega-3 ingredients market in the United Kingdom is forecast to grow at a CAGR of 6.2% from 2026 to 2036, influenced by preventive health trends and clinical recommendations for omega-3 use in pregnancy and heart disease. From 2020 to 2024, demand stemmed mainly from the OTC supplement channel. Over the next decade, growth is expected to come from functional bakery, dairy fortification, and cognitive health-targeted gummies. Local nutraceutical brands are increasing imports of algal DHA concentrates for eco-friendly positioning, while regulatory clarity on EFSA claims is expected to boost market transparency.

• Cognitive support supplements are incorporating higher DHA concentrations.
• Functional bakery and dairy brands are exploring omega-3 enrichment.
• Eco-conscious consumers are favoring algal-sourced omega-3 ingredients.

Demand Analysis for EPA DHA Omega-3 Ingredients Market in the United States

The United States EPA DHA omega-3 ingredients market is projected to grow at a CAGR of 5.5% during the forecast period, supported by an aging population, sports nutrition trends, and prescription-grade omega-3 formulations. Between 2020 and 2024, consumption was driven by heart health supplements and fortified beverages. Going forward, omega-3 usage will expand through direct-to-consumer personalized nutrition services, as well as higher inclusion in protein bars and ready-to-drink shakes. Regulatory pressure for heavy metal testing is also reshaping sourcing practices, favoring refined fish oils and algae-based concentrates.

• Personalized nutrition brands are customizing EPA-DHA dosages by health profile.
• Clean-label sports beverages are incorporating omega-3s for recovery support.
• Regulatory focus on purity is driving demand for ultra-refined omega-3 oils.

Competitive Aligners for Market Players

The EPA DHA omega-3 ingredients market is moderately concentrated and undergoing rapid structural change through acquisition. Koninklijke DSM holds an estimated 24.6% share in 2026, with BASF (now largely transferred to Louis Dreyfus Company), Nordic Naturals, Clover Corporation, Omega Protein, Copeinca, Solutex, Epax Norway, Croda International, Arista Industries, GC Rieber, OLVEA, and Lysi as significant competitors. Louis Dreyfus Company's October 2025 completion of the BASF Food and Health Performance Ingredients acquisition integrates BASF's established omega-3 formulation capabilities including microencapsulation technology and GRAS-certified concentrate production into LDC's global commodity and specialty ingredient distribution scale. [1]

KD Pharma Group's December 2025 agreement to acquire dsm-firmenich's food-grade oil distribution and supply business, following its earlier 2024 and 2025 consolidation of dsm-firmenich's marine lipids business and MEG-3 brand, positions KD Pharma as the largest pharmaceutical and nutraceutical omega-3 producer by combining dsm-firmenich's clinical-grade concentrate manufacturing with its own established pharmaceutical omega-3 production infrastructure. [2] Corbion's January 2026 Chinese regulatory approval for algae-based omega-3 DHA products opens the world's largest functional food and supplement market to algae DHA, providing Corbion with first-mover regulatory approval advantage in China's expanding infant formula and dietary supplement omega-3 ingredient demand.

Buyer concentration is high in the pharmaceutical omega-3 segment, where Amarin, AstraZeneca, and other prescription omega-3 drug producers require GMP-certified EPA and DHA concentrates at highly specific purity specifications. Dietary supplement contract manufacturers represent the broadest buyer base across omega-3 ingredient quality grades.

Recent Developments

• October 2025: Louis Dreyfus Company successfully completed the acquisition of BASF's Food and Health Performance Ingredients business, including its omega-3 oil portfolio for human nutrition. This transaction transfers BASF's established omega-3 production and formulation capabilities into LDC's global food and health ingredients distribution infrastructure, reducing the number of independent production-scale omega-3 ingredient suppliers. [1]
• December 2025: KD Pharma Group signed a definitive agreement to acquire the distribution and supply business for food-grade oils from dsm-firmenich. This follows KD Pharma's earlier consolidation of dsm-firmenich's marine lipids business including the MEG-3 brand, solidifying KD Pharma's position as the world's leading producer of omega-3 fatty acids for pharmaceutical and nutraceutical markets by integrating a wider range of food-grade lipid solutions. [2]
• January 2026: Aker BioMarine announced expansion in the Indian market, introducing Revervia, a high-concentration algae-based DHA solution produced through natural fermentation rather than chemical concentration, alongside establishment of strategic leadership partnerships ahead of Vitafoods India 2026 to develop the algae omega-3 category in the high-growth Indian dietary supplement market. [3]

Key Players in EPA DHA Omega 3 Ingredients Market

• Koninklijke DSM N.V.
• BASF SE
• Nordic Naturals Inc.
• Clover Corporation
• Omega Protein
• Copeinca ASA
• Solutex
• Epax Norway AS
• Croda International Plc
• Arista Industries Inc.
• GC Rieber
• OLVEA
• Lysi

Scope of the Report

Metric	Value
Quantitative Units	USD 3.62 billion (2026) to USD 6.80 billion (2036), at a CAGR of 6.5%
Market Definition	The EPA DHA omega-3 ingredients market covers EPA and DHA long-chain omega-3 polyunsaturated fatty acid ingredients from marine oil, algae oil, and high-purity concentrate sources for dietary supplement, functional food, pharmaceutical, infant formula, and pet food applications.
Product Segmentation	DHA, EPA
Source Segmentation	Algae Oil, Anchovy/Sardine Oils, High Concentrates, Medium Concentrates, Low Concentrates, Tuna Oil, Cod Liver Oil, Salmon Oil, Krill Oil, Menhaden Oil
Application Segmentation	Dietary Supplements, Functional Food, Pharmaceutical Food, Infant Food, Pet and Animal Feed, Others
Regions Covered	North America, Latin America, Europe, East Asia, South Asia, Oceania, Middle East and Africa
Countries Covered	China, India, Germany, France, United Kingdom, United States, Brazil, Japan, South Korea, Australia and 40 plus countries
Key Companies Profiled	Koninklijke DSM N.V., BASF SE, Nordic Naturals Inc., Clover Corporation, Omega Protein, Copeinca ASA, Solutex, Epax Norway AS, Croda International Plc, Arista Industries Inc., GC Rieber, OLVEA, Lysi
Forecast Period	2026 to 2036
Approach	Hybrid bottom-up and top-down market modeling validated through primary interviews with EPA DHA omega-3 ingredient producers and dietary supplement contract manufacturers, supported by LDC and KD Pharma acquisition documentation and Aker BioMarine corporate expansion announcements

EPA DHA Omega 3 Ingredients Market Analysis by Segments

Product

• DHA (53.6% share, 2026)
• EPA

Source

• Algae Oil (28.4% share, 2026)
• Anchovy/Sardine Oils
• High Concentrates
• Medium Concentrates
• Low Concentrates
• Tuna Oil
• Cod Liver Oil
• Salmon Oil
• Krill Oil
• Menhaden Oil

Application

• Dietary Supplements (37.2% share, 2026)
• Functional Food
• Pharmaceutical Food
• Infant Food
• Pet and Animal Feed
• Others

Region

• North America: USA (5.5% CAGR), Canada, Mexico
• Latin America: Brazil (4.9% CAGR), Argentina, Chile, Rest of Latin America
• Europe: Germany (7.5% CAGR), France (6.8% CAGR), UK (6.2% CAGR), Italy, Spain, Benelux, Nordics, Rest of Europe
• East Asia: China (8.8% CAGR), Japan, South Korea
• South Asia: India (8.1% CAGR), Indonesia, Malaysia, Thailand, Rest of South Asia
• Oceania: Australia, New Zealand
• Middle East & Africa: Saudi Arabia, UAE, South Africa, Rest of Middle East & Africa

Bibliography

• [1] Nutraceutical Business Review / Louis Dreyfus Company. (2025). BASF Completes Sale of Food and Health Performance Ingredients Business to Louis Dreyfus Company Including Omega-3 Oil Portfolio. Corporate Announcement, October 2025.
• [2] KD Pharma Group. (2025). KD Pharma Group Signs Definitive Agreement to Acquire Distribution and Supply Business for Food-Grade Oils from dsm-firmenich. Corporate Press Release, December 2025.
• [3] Aker BioMarine. (2026). Aker BioMarine Expands Presence in India Through Strategic Leadership Partnerships and Revervia Algae DHA Product Innovation Ahead of Vitafoods India 2026. Corporate Press Release, January 2026.
• [4] Global Omega-3 Day. (2026). Global Omega-3 Day 2026: Highlights the Importance of EPA DHA Omega-3s Throughout Life. Industry Report, February 2026.
• [5] Corbion. (2026). Corbion Gains Chinese Approval for Algae-Based Omega-3 DHA Products. Corporate Announcement, January 2026.

This Report Addresses

• Market intelligence to enable EPA DHA omega-3 ingredient sourcing strategy, supplier dual-qualification planning, and algae DHA versus marine oil sourcing matrix development for dietary supplement, infant formula, and functional food manufacturers
• Market size estimation and 10-year revenue forecasts from 2026 to 2036, incorporating LDC-BASF and KD Pharma-dsm-firmenich consolidation effects on supplier concentration dynamics and Aker BioMarine algae DHA India expansion market access modeling
• Growth opportunity mapping across DHA and EPA product types and Algae Oil versus marine oil source routes with emphasis on algae DHA cost trajectory reaching marine oil concentrate parity in premium applications by approximately 2028
• Segment and regional revenue forecasts covering product, source, and application dimensions with country-level CAGR analysis for China, India, Germany, France, the UK, and the USA
• Competition strategy assessment including DSM omega-3 portfolio scale, LDC-BASF integrated distribution advantage, KD Pharma pharmaceutical-grade consolidation, Nordic Naturals retail brand positioning, and Corbion and Aker BioMarine algae DHA competitive trajectory
• Regulatory impact analysis covering EFSA omega-3 health claim approvals for cardiovascular and cognitive applications, FDA GRAS status for algae DHA and marine oil EPA DHA, infant formula DHA fortification regulatory requirements by market, and China SAMR novel ingredient approval processes for algae DHA
• Supply chain analysis covering Peruvian anchovy fishmeal quota impact on sardine and anchovy omega-3 oil supply, krill oil Southern Ocean quota management, algae fermentation capacity scale-up economics, and sustainability certification including MSC and IFFO RS for marine oil omega-3 sourcing
• Market report delivery in PDF, Excel, PPT, and interactive dashboard formats for executive and operational use